LncRNA HOTAIR与BRCA-1在胃癌组织中的表达水平与顺铂化疗抵抗的影响
| 作者: |
1张伟,
1尹晓东
1 滨海县人民医院肿瘤科，江苏 滨海 224500 |
| 通讯: |
尹晓东
Email: yinxd2008@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2020.02.005 |
| 基金: | 盐城市科技计划项目(YK2016114)。 |
摘要
目的：研究lncRNA HOTAIR与BRCA-1在胃癌组织中的表达水平与顺铂化学药物治疗(以下简称化疗)抵抗的相关性。方法：选择2014年2月至2016年5月滨海县人民医院收治的胃癌根治术后并接受顺铂进行化疗的120例患者。采用实时定量PCR法检测所有患者胃癌组织、配对正常组织中lncRNA HOTAIR和BRCA-1的表达水平。比较患者胃癌组织与正常组织中lncRNA HOTAIR，BRCA-1表达水平，分析lncRNA HOTAIR与BRCA-1的表达与顺铂化疗效果的相关性。结果：在lncRNA组患者胃癌组织中lncRNA HOTAIR表达阳性者73例(60.8%)，相对表达水平为7.63±0.14；在正常组织中lncRNA HOTAIR表达阳性者26例(21.7%)，相对表达水平为2.32±0.06；lncRNA HOTAIR表达阳性者使用顺铂化疗2年的无复发率为8.33%(10例)，阴性患者2年的无复发率为16.67%(20例)。在BRCA-1组患者胃癌组织中BRCA-1表达阳性者70例(58.3%)，相对表达水平为15.39±4.28；在正常组织中BRCA-1表达阳性者4例(3.3%)，相对表达水平为5.71±2.13；BRCA-1表达阳性者使用顺铂化疗2年的无复发率为5.00%(6例)，阴性患者2年的无复发率为14.17%(17例)。结论：LncRNA HOTAIR及BRCA-1在胃癌组织中的表达量显著高于正常组织，与顺铂化疗抵抗具有一定的关联性，这两种标志物可作为胃癌患者术后化疗药物选择及预后判断的参考依据。
关键词：
胃癌；长链非编码RNA HOTAIR；乳腺癌易感基因1；顺铂化疗抵抗
Expression of lncRNA HOTAIR and BRCA-1 in gastric cancer and the effect of cisplatin resistance to chemotherapy
CorrespondingAuthor: YIN Xiaodong Email: yinxd2008@163.com
DOI: 10.3978/j.issn.2095-6959.2020.02.005
Foundation: This work was supported by Yancheng Science and Technology Plan Project Foundation, China (YK2016114).
Abstract
Objective: To study the correlation between the expression level of lncRNA HOTAIR and BRCA-1 in gastric cancer tissues and cisplatin chemotherapy resistance. Methods: A total of 120 patients who underwent radical surgery for gastric cancer and received cisplatin chemotherapy from February 2014 to May 2016 were enrolled. Real-time PCR was used to detect the expression levels of lncRNA HOTAIR and BRCA-1 in gastric cancer tissues and matched normal tissues of all patients. The expression levels of lncRNA HOTAIR and BRCA-1 in two tissues were compared; and the correlation between the expression of lncRNA HOTAIR and BRCA-1 and the effect of cisplatin chemotherapy was analyzed. Results: In the LncRNA group, the expression of LncRNA HOTAIR was 73 cases (60.8%) , and the relative expression level was 7.63±0.14. In normal tissues, the expression of LncRNA HOTAIR was 26 cases (21.7%), the relative expression level was 2.32±0.06. Patients with positive expression of LncRNA HOTAIR had a recurrence rate of 8.33% (10 cases) with cisplatin chemotherapy for 2 years, and 16.67% (20 cases) of negative patients with 2 years. In the BRCA-1 group, the positive expression of BRCA-1 in gastric cancer tissues was 70 cases (58.3%) and the relative expression level was 15.39±4.28. The positive expression of BRCA-1 in normal tissues was 4 cases (3.3%) and the relative expression level was 5.71±2.13. The 2-year relapse-free rate of BRCA-1 expression patients treated with cisplatin chemotherapy was patients with positive BRCA-1 expression had a recurrence-free rate of 5.00% (6 cases) for 2 years with cisplatin chemotherapy and 14.17% (17 cases) for negative patients for 2 years. Conclusion: The expression levels of lncRNA HOTAIR and BRCA-1 in gastric cancer tissues are significantly higher than those in normal tissues, and have a certain correlation with cisplatin chemotherapy resistance. These two biomarkers can be used as reference for chemotherapy drug selection and prognosis in patients with gastric cancer.
Keywords：
gastric cancer; long chain non-coding RNA HOTAIR; breast cancer susceptibility gene 1; cisplatin chemotherapy resistance